Skip to main content
Livermore
Livermore
ZHEN

Superstring Capital Management LP

SEC CIK
0001931118
Latest filing
Aug 14, 2026

Holdings in Q1 2024

Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.

Institution overview
Positions
37
+7 vs. Q4 2023
Portfolio value
$151.2M
+$11.1M (+7.9%) vs. Q4 2023
Filed
May 15, 2024
SEC
Holdings of Superstring Capital Management LP in Q1 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
CYTKCytokinetics IncCOM NEW278,915$19.6M12.9%+101,312+57.0%AddedHistory
NKTXNkarta, Inc.COM1,189,193$12.9M8.5%+841,812+242.3%AddedHistory
ETNB89bio, Inc.COM941,287$11.0M7.2%−80,190−7.9%ReducedHistory
BBIOBridgeBio Pharma, Inc.COM353,507$10.9M7.2%+147,181+71.3%AddedHistory
SVRASavara IncCOM2,065,144$10.3M6.8%+1,250,878+153.6%AddedHistory
IDYAIDEAYA Biosciences, Inc.COM217,070$9.53M6.3%−34,225−13.6%ReducedHistory
FATEFate Therapeutics IncCOM920,476$6.76M4.5%+72,653+8.6%AddedHistory
DAWNDay One Biopharmaceuticals, Inc.Stock349,679$5.78M3.8%−29,947−7.9%ReducedHistory
ROIVRoivant Sciences Ltd.SHS531,019$5.60M3.7%+204,858+62.8%AddedHistory
IONSIonis Pharmaceuticals IncCOM120,896$5.24M3.5%−68,722−36.2%ReducedHistory
MRNSMarinus Pharmaceuticals, Inc.COM NEW565,550$5.11M3.4%+103,106+22.3%AddedHistory
CABACabaletta Bio, Inc.COM290,797$4.96M3.3%+290,797NewHistory
URGNUroGen Pharma Ltd.COM288,267$4.32M2.9%+32,837+12.9%AddedHistory
VRNAVerona Pharma plcSPONSORED ADS259,383$4.17M2.8%+135,343+109.1%AddedHistory
JBIOJade Biosciences, Inc.COM110,264$3.26M2.2%+110,264NewHistory
APGEApogee Therapeutics, Inc.COM44,868$2.98M2.0%+44,868NewHistory
AXSMAxsome Therapeutics, Inc.COM36,607$2.92M1.9%+20,428+126.3%AddedHistory
DYNDyne Therapeutics, Inc.COM99,822$2.83M1.9%+99,822NewHistory
PRAXPraxis Precision Medicines, Inc.COM NEW40,119$2.45M1.6%+40,119NewHistory
ALLOAllogene Therapeutics, Inc.COM521,249$2.33M1.5%+299,137+134.7%AddedHistory
KROSKeros Therapeutics, Inc.COM33,828$2.24M1.5%−40,821−54.7%ReducedHistory
PYXSPyxis Oncology, Inc.COMMON STOCK493,759$2.10M1.4%+493,759NewHistory
ASNDAscendis Pharma A/SSPONSORED ADR12,754$1.93M1.3%+12,754NewHistory
PEPGPepGen Inc.COM114,385$1.68M1.1%+114,385NewHistory
TRMLTourmaline Bio, Inc.COM69,972$1.60M1.1%+69,972NewHistory
ALLKAllakos Inc.COM1,233,739$1.55M1.0%+1,233,739NewHistory
CTMXCytomX Therapeutics, Inc.COM679,403$1.48M1.0%+679,403NewHistory
ANNXAnnexon, Inc.COM155,728$1.12M0.7%+155,728NewHistory
Avidity Biosciences, Inc.05370A108COM37,031$945.0K0.6%+37,031New–
LYRALyra Therapeutics, Inc.COM145,284$903.7K0.6%+145,284NewHistory
INZYInozyme Pharma, Inc.COM112,739$863.6K0.6%−11,205−9.0%ReducedHistory
AUPHAurinia Pharmaceuticals Inc.COM98,691$494.4K0.3%+98,691NewHistory
KALVKalVista Pharmaceuticals, Inc.COM32,025$379.8K0.3%+32,025NewHistory
ALPNAlpine Immune Sciences, Inc.COM9,038$358.3K0.2%+9,038NewHistory
SPRBSpruce Biosciences, Inc.COM440,225$346.0K0.2%+321,411+270.5%AddedHistory
Ys Biopharma Co LtdG9845F109ORDINARY SHARES307,920$215.5K0.1%00.0%Unchanged–
SYSo-Young International Inc.SPONSORED ADS182,742$199.2K0.1%−613,317−77.0%ReducedHistory

Sold out since Q4 2023 (10)

Positions held at the end of Q4 2023 that are gone from this filing.

Positions of Superstring Capital Management LP sold out since Q4 2023
SecurityClassShares in Q4 2023Value in Q4 2023% of portfolio in Q4 2023History
IMGNImmunoGen, Inc.COM598,072$17.7M12.7%History
PTGXProtagonist Therapeutics, IncCOM379,143$8.69M6.2%History
IMVTImmunovant, Inc.COM203,592$8.58M6.1%History
NBIXNeurocrine Biosciences IncStock29,346$3.87M2.8%History
LNTHLantheus Holdings, Inc.Stock54,896$3.40M2.4%History
SLRNACELYRIN, Inc.COM356,924$2.66M1.9%History
KRYSKrystal Biotech, Inc.COM16,086$2.00M1.4%History
QTRXQuanterix CorpCOM71,760$1.96M1.4%History
IMTXImmatics N.V.SHS79,213$834.1K0.6%History
FUSNFusion Pharmaceuticals Inc.COM45,801$440.1K0.3%History